Lofexidine information

Lofexidine
Clinical data
Trade names	Britlofex, Lucemyra, Kai Er Ding, others
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth (tablets)
ATC code	N07BC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Protein binding	80–90%
Metabolism	Liver (glucuronidation)
Elimination half-life	11 hours
Excretion	Kidney
Identifiers
	IUPAC name (RS)-2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole;
CAS Number	31036-80-3 ;
PubChem CID	30668;
DrugBank	DB04948 ;
ChemSpider	28460 ;
UNII	UI82K0T627;
KEGG	D08141 ;
ChEBI	CHEBI:51368 ;
ChEMBL	ChEMBL17860 ;
CompTox Dashboard (EPA)	DTXSID7023221 ;
Chemical and physical data
Formula	C11H12Cl2N2O
Molar mass	259.13 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc2;
	InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) ; Key:KSMAGQUYOIHWFS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lofexidine, sold under the brand name Lucemyra among others,^[1] is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal.^[2] It is taken by mouth.^[3] It is an α_2A adrenergic receptor agonist.^[3] It was approved for use by the Food and Drug Administration in the United States in 2018.^[3]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[4]

^ Cite error: The named reference FDA Approval was invoked but never defined (see the help page).
^ Cite error: The named reference BNF was invoked but never defined (see the help page).
^ ^a ^b ^c "FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults". U.S. Food and Drug Administration (FDA) (Press release). Retrieved 18 May 2018.
^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.

[FDA_Approval-1] Cite error: The named reference FDA Approval was invoked but never defined (see the help page).

[BNF-2] Cite error: The named reference BNF was invoked but never defined (see the help page).

[FDA2018-3] "FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults". U.S. Food and Drug Administration (FDA) (Press release). Retrieved 18 May 2018.

[4] New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.

Lofexidine information

and 26 Related for: Lofexidine information

Lofexidine

Opioid withdrawal

Propofol

Quetiapine

Propranolol

Cannabis

Dimenhydrinate

ATC code N07

Olanzapine

Prochlorperazine

Cannabis use disorder

Flunitrazepam

Xylazine

Chloral hydrate

Ethchlorvynol

Clozapine

Phenobarbital

Chlorpromazine

Psychiatry

Hypnotic

Clenbuterol

Risperidone

Temazepam

LSD

Ramelteon

Phenothiazine